MUC1 and ovarian carcinoma: showed that ovarian cancer models expressing MUC1, after anti-PD-L1 antibody treatment, exhibited increased T cell infiltration in tumors and extended survival, indicating MUC1’s potential in ovarian cancer immunotherapy (143).